« INDUSTRY NEWS
Sartorius Stedim Biotech Announces Off er To Acquire UK Company TAP Biosystems Group Plc
Sartorius Stedim Biotech, a leading global supplier for the pharmaceutical and biotech industries, today made a cash off er to acquire the UK company TAP Biosystems Group plc (TAP Biosystems) through its wholly owned subsidiary Sartorius Stedim Biotech GmbH. The proposed transaction, which is subject to customary closing conditions, including the approval of TAP’s shareholders, values the equity of TAP Biosystems at approximately €33 million. The transaction has been unanimously approved by the boards of directors of both companies and is expected to close at the end of 2013.
In making the announcement, Joachim Kreuzburg, the Chief Executive of Sartorius Stedim Biotech, stated, “TAP Biosystems’
fermentors
are a great fi t extending our reach into the small scale cell culture applications. Adding capabilities in the early steps of upstream bioprocessing will enable us to provide our biopharma customers highly eff ective and scalable solutions to accelerate cell line selection, speed-up process development and ultimately help them bringing their biologics to market faster.”
TAP Biosystems plc specializes in the design and development of small-scale, multi-parallel fermentation systems particularly for biopharmaceutical applications. Furthermore TAP Biosystem’s portfolio includes automated cell processing systems and other bench top equipment.
Welcoming the acquisition, David Newble, CEO of TAP Biosystems, said, “As a market leader in bioprocessing technologies with a strong position in fermentation, Sartorius Stedim Biotech is well-placed to maximize the opportunities of our novel, highly innovative cell culture technologies. We look forward to joining such a well- recognized organization as Sartorius Stedim that will enable us to grow our business further with a wealth of complementary technologies and products.”
Catalent Applied Drug Delivery Institute Appoints Professor Claus- Michael Lehr to Advisory Board
The Catalent Applied Drug Delivery Institute announced that it has appointed Professor Claus-Michael Lehr, to the Institute’s Advisory Board.
Professor Lehr has spent more than 15 years leading research into ways to overcome biological barriers to eff ective drug delivery, and the development and formulation of appropriate carriers to transport active pharmaceutical and biopharmaceutical molecules to desired targets. He has co-authored many notable publications on the development of sophisticated in-vitro models that more accurately represent the epithelial cells and tissues concerned in transport, and
Meissner’s New Product Labels Allow for Easy Transfer of Product Information to Production Records
Meissner provides an enhanced level of customer convenience by adding a defi ned “peel and stick” area to its One-Touch® single-use systems product labels. This added feature gives operators the ability to transfer critical product information from the packaging, which is typically discarded when the product is deployed, to documentation that will be saved for future reference, or to the rigid outer container in which the biocontainer assembly is being deployed. This quick, easy data transfer process will help ensure accuracy of production records and future product tracking.
The size, shape and content contained on Meissner’s One-Touch® single-use systems product label will remain the same. The new label, however, will allow the following information to be retained for production records and documentation: the product part number and description, tracking number, lot number, serial number, expiration date and sterility information (if supplied sterile). A phone number to call for technical assistance will also be retained.
Capsugel Expands Global Manufacturing for Finished Dosage Forms
Dosage Form Solutions (DFS) business unit unveiled extensive upgrades and expansions to three of its manufacturing facilities in the United States and Europe, deepening the company’s fi nished dosage form capabilities as part of its LIPIDEX® technology platform. The multi-million dollar investments broaden the company’s global capabilities to handle hormonal as well as high- potent compounds for soft gelatin and liquid-fi ll hard capsules (LFHC), responding
www.americanpharmaceuticalreview.com | | 113
the application of nanotechnology to improve in-vivo delivery to such therapeutic targets.
He is currently Head of the Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, Germany and Co- founder and Head of the Department “Drug Delivery” (DDEL) of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS).
“The sharing of knowledge is key to the Institute’s mission to drive the early adoption of advanced drug delivery technologies,” Professor Lehr commented. “Collaboration across industry and academia will encourage the innovation of better products and their eff ective delivery, with fewer unwanted side eff ects.”
“Professor Lehr’s research experience in drug delivery, coupled with his outstanding connections within our industry, will be great assets to the Institute,” commented Terry Robinson, Executive Director of the Catalent Applied Drug Delivery Institute. “We look forward to the valuable support and guidance of our advisory board members.”
»
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156